ClinicalTrials.gg
Active, not recruitingNCT04524871MORPHEUS-LIVERUpdated Sep 3, 2026

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

A Phase 1/2 interventional study of Atezolizumab and Bevacizumab 15 mg/kg in Advanced Liver Cancers, sponsored by Hoffmann-La Roche. Active, not recruiting at 32 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing bevacizumab in Liver Neoplasms — 4 open to participants now, 9 under way, 1 of them phase 3. Bevacizumab · Liver Neoplasms.

Planned enrollment
3rd of 30
518 · median 40
Started
2020
the only one that year
Phase 1/2
2 of 30
none open now
Registered
20th of 30
by date
Lead sponsor
4 of 30
Hoffmann-La Roche

Among the 30 studies testing bevacizumab in Liver Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 20th registered.

Liver Neoplasms

1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

4 of the 30 studies testing bevacizumab in Liver Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing bevacizumab in Liver Neoplasms, or all of them as a file.
02

Study summary

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.

Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.

03

Conditions studied

  • Advanced Liver Cancers

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Stage 1

  • (ECOG) Performance Status of 0 or 1 within 7 days prior to randomization
  • Locally advanced or and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of
  • Liver Diseases criteria in cirrhotic patients
  • class A within 7 days prior to randomization
  • Disease that is not amenable to curative surgical and/or locoregional therapies
  • No prior systemic treatment for HCC
  • >= 3 months
  • Availability of a representative tumor specimen that is suitable for determination of and/or additional biomarker status via central testing

Stage 1 and Stage 2

  • according to v1.1
  • Adequate hematologic and end-organ function within 7 days prior to initiation of study treatment
  • Documented virology status of hepatitis, as confirmed by screening tests for virus - (HBV) and virus (HCV)
  • Negative test at screening
  • For women of : agreement to remain abstinent or use and for men: agreement to remain abstinent or use contraception, and agreement to refrain from donating sperm

Stage 2

  • ECOG Performance Status of 0, 1, or 2
  • Ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity not related to atezolizumab or RO7247669 or loss of clinical benefit as determined by the investigator while receiving Stage 1 treatment
  • Availability of a tumor specimen from a performed upon discontinuation of Stage 1 (if deemed clinically feasible)

NKT2152-Containing Arm:

  • Total ≤ 1.5 X in the absence of Gilbert's disease (≤ 3.0 X ULN if Gilbert's disease)
  • /ALT ≤ 2.5 X ULN (≤ 5 X ULN if liver metastases present)

Exclusion criteria

Exclusion Criteria:

Stage 1

  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies or inhibitors targeting HIF2a
  • Treatment with therapy within 28 days prior to initiation of study
  • Treatment with locoregional therapy to liver within 28 days prior to initiation of study, or non-recovery from side effects of any such procedure
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or at high risk for bleeding
  • Prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study
  • AEs from prior anti-cancer therapy that have not resolved to Grade \<= 1 or better, with the exception of alopecia of any grade
  • Inadequately controlled hypertension
  • History of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease
  • History of hemoptysis within 1 month prior to initiation of study
  • Evidence of bleeding diathesis or significant coagulopathy
  • Current or recent use of aspirin (>325 mg/day) or treatment with clopidogrel, dipyramidole, ticlopidine, or cilostazol
  • Current or recent use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose
  • Core or other minor surgical procedure within 3 days prior to initiation of study
  • History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess, intestinal obstruction and/or clinical signs/symptoms of GI obstruction
  • Evidence of abdominal free air not explained by paracentesis or recent surgery
  • Serious, non-healing/dehiscing wound, active ulcer, or untreated bone fracture
  • Grade >=2 proteinuria
  • disease involving major airways/blood vessels, or centrally located mediastinal tumor masses of large volume
  • History of intra-abdominal inflammatory process
  • Radiotherapy within 28 days or abdominal/pelvic radiotherapy within 60 days prior to initiation of study with the exception of palliative radiotherapy to bone lesions within 7 days prior to initiation of study
  • Major surgery, open biopsy, or significant traumatic injury within 28 days prior to initiation of study; or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to initiation of study; or anticipation of need for major surgery during study or non-recovery from side effects of any such procedure
  • Chronic daily treatment with NSAID
  • Eligible only for control arm

Stage 1 and 2

  • Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • History of hepatic encephalopathy
  • Moderate or severe ascites
  • and coinfection
  • Symptomatic, untreated, or actively progressing
  • History of
  • Uncontrolled tumor-related pain
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Uncontrolled or symptomatic hypercalcemia
  • Active or history of disease or immune deficiency
  • History of IPF, organizing pneumonia, drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
  • Active TB
  • Significant CV disease within 3 months prior to initiation of study, unstable arrhythmia, or unstable angina
  • Major surgery, other than for diagnosis, within 4 weeks prior to initiation of study, or anticipated major surgery during study
  • History of other than HCC within 5 years prior to screening
  • Severe infection within 4 weeks prior to initiation of study
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known allergy or to any of the study drugs or any of their
  • Treatment with systemic immunostimulatory, agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study
  • Grade >= 3 hemorrhage or bleeding event within 8 weeks prior to initiation of study treatment
  • Patients entering Stage 2: immunotherapy-related adverse events that have not resolved to Grade 1 or better or to baseline at time of consent
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
518 participants (estimated)

Study arms

  • Active comparator
    Stage 1: Atezolizumab + Bevacizumab

    Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab 15 mg/kg

  • Experimental
    Stage 1: Atezolizumab + Bevacizumab + Tiragolumab

    Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab 15 mg/kg · Drug: Tiragolumab

  • Experimental
    Stage 1: Atezolizumab + Bevacizumab + Tocilizumab

    Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab 15 mg/kg · Drug: Tocilizumab

  • Experimental
    Stage 1: Atezolizumab + Bevacizumab + TPST-1120

    Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab 15 mg/kg · Drug: TPST-1120

  • Experimental
    Stage 1: Tobemstomig 2100 mg Q2W + Bevacizumab

    Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Bevacizumab 15 mg/kg · Drug: Tobemstomig 2100 mg · Drug: Bevacizumab 10 mg/kg

  • Experimental
    Stage 1: Tobemstomig 600 mg Q3W + Bevacizumab

    Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Bevacizumab 15 mg/kg · Drug: Tobemstomig 600 mg

  • Experimental
    Stage 1: Tobemstomig 1200 mg Q3W + Bevacizumab

    Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Bevacizumab 15 mg/kg · Drug: Tobemstomig 1200 mg

  • Experimental
    Stage 1: Atezolizumab + Bevacizumab + ADG126

    Participants will receive atezolizumab plus bevacizumab plus ADG126 until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab 15 mg/kg · Drug: ADG126

  • Experimental
    Stage 1: Atezolizumab + Bevacizumab + IO-108 1200 mg Q3W

    Participants will receive atezolizumab plus bevacizumab plus IO-108 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab 15 mg/kg · Drug: IO-108 1200 mg

  • Experimental
    Stage 1: Atezolizumab + Bevacizumab + NKT2152

    Participants will receive atezolizumab plus bevacizumab plus NKT2152 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab 15 mg/kg · Drug: NKT2152

  • Experimental
    Stage 1: Atezolizumab + Bevacizumab+ IO-108 1800 mg Q3W

    Participants will receive atezolizumab plus bevacizumab plus IO-108 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic andbiochemical data, local biopsy results (if available), and clinical status

    Drug: IO-108 1800 mg

Interventions

  • Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

    Also known as: Tecentriq

  • DrugBevacizumab 15 mg/kg

    Drug page: Bevacizumab

    Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

    Also known as: Avastin

  • Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

  • Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.

    Also known as: Actemra

  • DrugTPST-1120

    TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.

  • Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.

  • DrugBevacizumab 10 mg/kg

    Drug page: Bevacizumab

    Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.

    Also known as: Avastin

  • Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

  • Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.

  • DrugADG126

    ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).

  • IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.

  • NKT2152 will be administered by mouth.

  • IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR, defined as the proportion of participants with a complete response or partial response on two consecutive occasions \>=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.

    Time frame: From randomization until disease progression or loss of clinical benefit (up to approximately 7-9 years)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1.

    Time frame: Randomization to first occurrence of disease progression or death from any cause in Stage 1 (up to approximately 7-9 years)

  2. Overall Survival (OS)

    OS after randomization, defined as the time from randomization to death from any cause.

    Time frame: Randomization to death from any cause (up to approximately 7-9 years)

  3. OS at Specific Timepoints

    OS at a specific timepoint, such as Month 6

    Time frame: Randomization to a specific timepoint, such as Month 6

  4. Duration of Response (DOR)

    DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1.

    Time frame: First occurrence of a documented objective response to disease progression or death (up to approximately 7-9 years)

  5. Disease Control

    Disease control, defined as stable disease for \>=12 weeks or a complete or partial response, as determined by the investigator according to RECIST v1.1.

    Time frame: Randomization to end of study (approximately 7-9 years)

  6. Percentage of Participants With Adverse Events During Stage 1

    Time frame: Baseline through the end of the study (approximately 7-9 years)

  7. Percentage of Participants With Adverse Events During Stage 2

    Time frame: Baseline through the end of the study (approximately 7-9 years)

07

Study locations

32 sites
08

References and documents

Publications

  • Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Edubilli TR, Mahrus S, Secrest MH, Shemesh CS, Yu N, Hack SP, Cha E, Gane E. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. Lancet Oncol. 2025 Feb;26(2):214-226. doi: 10.1016/S1470-2045(24)00679-X. Epub 2025 Jan 21. PubMed 39855251 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Jul 2027, 80 months after the start.

Of 33 phase 1/2 interventional studies under Liver Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 72. This study's planned 80 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2020
First posted
Aug 24, 2020
StartActual
Nov 1, 2020
Primary completionEst.
Jul 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04524871
Lead sponsor
Hoffmann-La Roche
Collaborators
Adagene Inc, Tempest Therapeutics, NiKang Therapeutics, Inc., Immune-Onc Therapeutics
Responsible party
Sponsor
First posted
Aug 24, 2020
Start date
Nov 1, 2020
Primary completion
Jul 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Tiragolumab · Tocilizumab · Tobemstomig · Muzastotug · Anti-LILRB2 Monoclonal Antibody IO-108 · Imdatifan

Start the discussion